Skip to main content

Table 3 Baseline characteristics of patients with ETS ≥20% compared to ETS < 20% (no ETS)

From: Early tumor shrinkage and response assessment according to mRECIST predict overall survival in hepatocellular carcinoma patients under sorafenib

Variable Total n = 115 ETS ≥ 20% n = 32 ETS < 20% n = 83 p-value
Sex
Female 15 (13.0%) 7 (21.8%) 8 (9.6%) 0.0808
Male 100 (87.0%) 25 (78.1%) 75 (90.4%)
Age, years
Mean (SD) 65.3 (8.7) 67.4 (7.4) 64.5 (9.1) 0.1106
Median (IQR) 65.0 (12.0) 67.5 (12.0) 64.0 (13.0)
Age category, years
  ≥ 65 55 (47.8%) 13 (40.6%) 42 (50.6%) 0.3371
  > 65 60 (52.2%) 19 (59.4%) 41 (49.4%)
Ethnicity
Missing 10 (8.7%) 4 (12.5%) 6 (7.2%) 0.6299
Hispanic or Latin 5 (4.8%) 1 (3.1%) 4 (4.8%)
Other 100 (95.2%) 27 (84.3%) 73 (87.9%)
Race
Missing 11 (9.6%) 4 (12.5%) 7 (8.4%) 0.2052
Black 2 (1.9%) 0 2 (2.6%)
Other 3 (2.9%) 2 (7.1%) 1 (1.3%)
White 99 (95.2%) 26 (92.9%) 73 (96.1%)
ECOG status
0 90 (78.3%) 24 (75.0%) 66 (79.5%) 0.5986
1 25 (21.7%) 8 (25.0%) 17 (20.5%)
HCC diagnosis by
Missing 2 (1.7%) 0 2 (2.4%) 0.6537
EASL criteria 50 (43.5%) 12 (37.5%) 38 (45.8%)
Histology 50 (43.5%) 16 (50.0%) 34 (41.0%)
Other 13 (11.3%) 4 (12.5%) 9 (10.8%)
Hepatitis B
No 104 (90.4%) 29 (90.6%) 75 (90.4%) 0.9657
Yes 11 (9.6%) 3 (9.4%) 8 (9.6%)
Hepatitis C
No 81 (70.4%) 27 (84.4%) 54 (65.1%) 0.0419
Yes 34 (29.6%) 5 (15.6%) 29 (34.9%)
Alcohol etiology
No 63 (54.8%) 17 (53.1%) 46 (55.4%) 0.8245
Yes 52 (45.2%) 15 (46.9%) 37 (44.6%)
Previous therapies
TACE 28 (24.3%) 6 (18.8%) 22 (26.5%) 0.3851
TAE 2 (1.7%) 0 2 (2.4%) 0.3757
Resection 21 (18.3%) 8 (25.0%) 13 (15.7%) 0.2454
RFA 12 (10.4%) 4 (12.5%) 8 (9.6%) 0.6528
Brachytherapy 5 (4.3%) 1 (3.1%) 4 (4.8%) 0.6897
Max. diameter of largest lesion
Mean (SD) 68.0 (59.6) 59.1 (41.3) 71.6 (65.3) 0.2127
Median (IQR) 57.0 (45.0) 50.0 (38.0) 59.5 (55.0)
Portal vein infiltration
Yes 60 (52.2%) 19 (59.4%) 41 (49.4%) 0.3371
Baseline metastasis
Yes 6 (5.2%) 0 6 (7.2%) 0.1182
BCLC
B 34 (29.6%) 8 (25.0%) 26 (31.3%) 0.5053
C 81 (70.4%) 24 (75.0%) 57 (68.7%)  
Up-to-7 criterion
Inside 17 (14.8%) 5 (15.6%) 12 (14.5%) 0.8744
Outside 98 (85.2%) 27 (84.4%) 71 (85.5%)
Total bilirubin (μmol/L)
Mean (SD) 16.1 (7.1) 15.3 (7.3) 16.3 (7.1) 0.3959
Median (IQR) 14.9 (10.0) 14.0 (9.3) 15.1 (9.9)
Albumin g/L
Mean (SD) 37.8 (8.3) 40.0 (6.1) 37.0 (8.9) 0.2368
Median (IQR) 39.0 (7.7) 40.0 (6.0) 38.9 (8.0)
ALBI score
Mean (SD) −2.5 (0.7) −2.7 (0.7) −2.4 (0.8) 0.1644
Median (IQR) −2.5 (0.8) −2.7 (0.7) −2.5 (0.8)
Child-Pugh score
A 105 (91.3%) 31 (96.8%) 74 (89.1%) 0.2792
B 10 (8.7%) 1 (3.1%) 9 (10.8%)
  1. ALBI albumin-bilirubin, BCLC Barcelona Clinic Liver Cancer, EASL European Association for the Study of the Liver, ECOG Eastern Cooperative Oncology Group, HCC hepatocellular carcinoma, IQR interquartile range, RFA radiofrequency ablation, SD standard deviation, TACE transarterial chemoembolization, TAE transarterial embolization